Presentation is loading. Please wait.

Presentation is loading. Please wait.

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe  Peter.

Similar presentations


Presentation on theme: "The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe  Peter."— Presentation transcript:

1 The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe  Peter L. Lakatos, Barbara D. Lovasz, Gyula David, Tunde Pandur, Zsuzsanna Erdelyi, Gabor Mester, Mihaly Balogh, Istvan Szipocs, Csaba Molnar, Erzsebet Komaromi, Petra A. Golovics, Zsuzsanna Vegh, Michael Mandel, Agnes Horvath, Miklos Szathmari, Lajos S. Kiss, Laszlo Lakatos  Journal of Crohn's and Colitis  Volume 7, Issue 5, Pages (June 2013) DOI: /j.crohns Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

2 Figure. 1 Overall rate of lymphoma in patients with IBD.
SIRIBD: 1.37, 95% CI: 0.44–4.26. SIRUC: 1.35, 95% CI: 0.34–5.42. SIRIBD: 1.41, 95% CI: 0.20–10.1. Journal of Crohn's and Colitis 2013 7, DOI: ( /j.crohns ) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

3 Figure. 2 Overall incidence rate of lymphoma in male patients with IBD. SIRmale: 2.40, 95% CI: 0.77–7.47. Journal of Crohn's and Colitis 2013 7, DOI: ( /j.crohns ) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions


Download ppt "The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe  Peter."

Similar presentations


Ads by Google